top of page

Free Biopharma Daily Stock Updates - 04/08/22

$XBI $90.34 | +-2.3%

 

Covid Updates

$NVAX +1.9% Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand.



Pipeline Updates

$AFMD -6.1% Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors. source


$CHRS -0.5% Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting. source


$ADAG -2.2% Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022. source


$GNCA -69.2% Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022. source


$XFOR -3.9% X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022. source


$ONCY -1.3% Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting. source


$CRDF -2.5% Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models. source


$CRDF -2.5% Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting. source


$ABCL -7.3% AbCellera Presents Data on T Cell Engager Platform at AACR 2022. source


$BPMC +1.8% Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer. source


$ONCY -1.3% Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting. source


$RUBY -45.6% Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability. source


$CDAK -3.1% Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells. source


$CMPI +1.8% Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting. source


$BCYC +24.5% Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting. source


$ZNTL -30.0% Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR. source


$CCCC -50.6% C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader. source


$AGEN -4.0% Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance. source


$ADAP -2.7% Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors. source


$BCRX -37.8% BioCryst Pauses Enrollment in BCX9930 Clinical Trials.



Business Updates

$KLDO -81.8% Kaleido Biosciences, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market, Inc. that the Company intends to voluntarily delist its common stock. source


$LYRA +22.2% LYRA THERAPEUTICS ANNOUNCES $100.5 MILLION PRIVATE PLACEMENT.


$RNLX -2.2% Renalytix plc - Successful completion of $30.0 million financing package.


 

Posted by DV/FS

0 comments

Comentarios


bottom of page